gutflix
GI learning, personalised

Summary

REOVIRUS COMBINED WITH A STING AGONIST ENHANCES ANTI-TUMOR IMMUNITY IN A MOUSE MODEL OF COLORECTAL CANCER

Yoshinori Mori

UEG Week Copenhagen 2023 | Poster

Colorectal

October 15, 2023

Combination treatment with oncolytic reovirus and STING agonist ADU-S100 enhanced antitumor immunity and induced regression of both treated and distant untreated tumors in a CT26 syngeneic mouse model of colorectal cancer.

KEY POINTS

- Combination treatment of reovirus and ADU-S100 induced significant regression in both the treated tumor and the untreated distant tumor in a dual-flank mouse model, while either agent alone did not significantly delay growth of the distant tumor.
- The combination treatment significantly prolonged survival of mice bearing dual tumors.
- Tumor-infiltrating lymphocyte profiling showed a significantly lower CD4:CD8 T cell ratio in both treated and untreated tumors from mice receiving combination treatment compared to untreated controls.
- Significant reduction in the ratio of regulatory T cells was detected in tumors treated with reovirus alone or the combination of reovirus and ADU-S100 compared to control.
- The authors conclude that the enhanced antitumor response was partially mediated by IFN-induced T cell activation and that this combination strategy may have potential as an immunotherapy against colorectal cancer.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/593e053c-743b-11ee-b1e2-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.